Our Innovative Medicines sales grew across both our US and ex US geographies, 3% in the US, 5% ex-US in constant currencies, with growth drivers now accounting for 56% of our IM sales. And in international markets, we generally tend to do well. When you think about our SG&A, we want to be at the median or better in the sector over time. So there's a little bit of time to continue to think about the different ways of capital allocation. Because on your IP slide, it says Cosentyx passes 2029 plus. Thanks for the question, Simon. But operator, let's take the next question, and we'll keep going till the mid of the hour. And as I mentioned with ligelizumab, data demonstrated superiority versus placebo, but not superiority versus Xolair. So just following up again on Pluvicto, just to reiterate on Steve's point. And as I mentioned, we're leveraging the Lutathera footprint, but also beginning to work already in bringing additional centers online in order to fully capture the earlier-line opportunities. We certainly have the aspiration to get to USD 2 billion, but it's going to depend on how many more markets we're actually able to get on to national programs. Yes. In terms of considerations. A. As you can see, overall, our full year results were in line with guidance, with a particularly strong Innovative Medicines performance. We've revised the full year guidance upwards, and Harry will speak more about that. A. So over the course of this year and really starting in 2023, we would expect the ex-US contributions to the brand to start to increase. And therefore, what proportion of the Sjgrens population, which is pretty large, that might that Phase III trial might apply to? So all on track. And we're also looking to progress within B-cell malignancies, where we believe an anti-BAFF receptor antibody could provide an additional option for these patients. Your next question comes from the line of Richard Vosser from JPMorgan. Certainly, we believe in the profile of the molecule and certainly our discussions with the US government, they're excited about the concept of a onetime subcu therapy. Now with respect to Europe, we maintain our leadership position amongst originator biologics in psoriasis and spondyloarthritis. There was a 38% reduction in the risk of death in these patients. However, important to note, underlying free cash flow is in line with expectations. I just wondered, as you're slipping into 2023, is it just slipping into 2023 or on the event rate that you're looking at, at the moment, is it a first half or second half '23 read? Q. I just wanted to return to Pluvicto. TRx, 131%. Question please on Sandoz. Scemblix, also continuing a solid launch momentum through quarter 3. Thanks, Marie-France. I'd love to just kind of get your thoughts there and then the evolution of the market as we see it for an injectable therapy. So just wanted a couple of pipeline questions very quickly. Again, we monitor should that change, we would inform you. YTB, which is indicated for DLBCL, in a small study of 16 patients, demonstrated a 73% CR rate at month 3. And we want to ensure that there is consistency in terms of these patients that we're recruiting because Sjgrens is a very diverse population of patients. Slide 1 - Samir Shah, Global Head Investor Relations. It's a large indication, lots of patients. And I think it's really premature for us to speculate, if there were a "sale," how we would use the cash. Latest updates: Novartis Enterprise Risk Management (PDF0.2MB) | Materiality Assessment. If you could just give us an update on the timing of the New Jersey and Indianapolis plants next year, are they still second quarter in the second half? President, Novartis Pharmaceuticals Susanne Schaffert President, Novartis Oncology John Tsai Head of Global Drug Development and CMO Richard Saynor CEO, Sandoz Karen Hale Chief Legal Officer Samir Shah Global Head Investor Relations ParticipantsCompany overview PharmaceuticalsOncology Financial reviewConclusion Appendix References The successful launches of Leqvio, Kesimpta, Lu-PSMA, which we believe has the potential to be a very significant asset, and Scemblix, where, again, we have the opportunity to build on a third-line approval and hopefully move into earlier lines of therapy. As you have seen, Sandoz has improved. And we really think it's midyear next year before you would expect to see any further acceleration beyond the linear path that we're on at the moment. On your second question in terms of go ahead. Important to note, we still need to do larger studies. And when you take a geographic view of the business, we had consistent growth across US, Europe and China in innovative medicines, driven by different brands in each case. Q. And we have our Italian site at Ivrea online and Millburn and Indianapolis are planned for 2023. So all of this to say that the foundations are in place for the second half. And core operating income is now expected to grow low single digit, revised upward from broadly in line. And then once Indianapolis comes online, we would be in a position where we can service the US from two manufacturing plants in the US, dedicate our European facilities to Europe and ex US, and then look at adding additional capacity in Asia and other markets over time. Q. I just wanted to ask on the business in China. So once the Millburn facility comes online, we've invested in that facility to have additional capacity, we would be well positioned already for that new indication and the demand surge. So right now, we have over 2,000 patients treated worldwide, which I think demonstrates the profile of this gene therapy and the confidence providers are having using this medicine. So that's kind of our mindset at the moment. Q. We do think to be successful in cardiovascular buy-and-bill, you have to be relatively infrequent, even quarterly, we'll have to see. We're advancing in SLE as well as in autoimmune hepatitis and expect additional data over the coming 12 months on these 2 indications. When I look at the latest prescriptions for Tafinlar and Mekinist, they seem to have gone more into a decline in Q4. So it's 35 on the slide, but we're up to 50, have ordered Leqvio. Vas, just on this your expectation of a linear trend to the middle of next year, with the two drivers of more doctors being set up to administer the drug and more patients per physician, I mean that does sound a little conservative because, I mean, that in itself should if both of those are increasing, that should drive more than linear growth. And that's where the focus is, that's where we're investing and that's where our footprint is working. Q. And in particular, I'm thinking of iptacopan versus Soliris/Ultomiris and other high-value infused drugs but also Kesimpta versus Ocrevus. Your next question comes from the line of Kerry Holford from Berenberg. And we also are progressing on track with our Phase III studies in the pre-taxane and hormone sensitive setting and we're also which would expand the patient population 3 to 4x and allow us to target a patient population to enable this to be a multibillion-dollar brand over time. We expect to submit our IV regulatory file in quarter 4. Get our Top Stocks with 50% off Premium Novartis (NVS) Investor Presentation - Slideshow Oct. 01, 2021 2:44 PM ET Novartis AG (NVS), NVSEF 1 Like SA Transcripts 131.07K Follower s The. I wonder if you could give us any more color at all in the centers that are currently using it. So we did have some stocking movements in the US. I mentioned that this is fully in our guidance for 2022. You can expect to see the typical quarter-over-quarter decline in Q1, followed by continued double-digit growth for the full year, fully on track to deliver on our USD 7 billion plus guidance. However, we do believe there's potential for the medicine in food allergy and CIndU, given there is no approved anti-IgE therapy in this indication. Looking ahead, we've had the accelerated approval converted to a regular approval based on 96-week data. For modeling purposes, we thought it would be very helpful to you to go into some details regarding the currency impact, especially given the recent appreciation of the US dollar. So we've already started recruitment in the pre-taxane study, and we're hoping to read out before the end of the year for the second line treatment. And that's, I think, the case we'll have to make. And then I think in neuroscience, it is very clinic- and situation-specific. The V-2P is a broader patient population where we're going globally, not only in the US, but across major geographies throughout the world. So Mark, I think it's important to note that we're looking at both grade 2, grade 3 patients in the study. And of course, solid tumors and hematology. But again, this is on the back of very good news. We look at larger assets. Q. But we would stay consistent with the balanced capital allocation approach which I outlined earlier, thinking through investing in the business versus returning value to shareholders. Your next question comes from the line of Florent Cespedes from Societe Generale. And so the results, the IDFS results, will be based on the overall population, and that's how the endpoints are designed. Is that a fair assessment? (Operator Instructions). That said, in the US, we would expect to be growing in the single-digit range in the next two years until we get our new indications and new formulations online, which we then think will give us the next wave of acceleration. Moving to Slide 34: Kisqali. At what breadth of enrollment is that likely to include in terms of the patient population? Patients receive Kisqali 400 milligrams per day for 36 months. On the first one, a few measures on our minds. Just as a reminder, we continue to view Sandoz as having the potential to be the leading generics company in the world driven by its biosimilars' presence and strength as well as key success factors which we reviewed on the previous call. Q1 in the US was a little bit weaker versus what we're expecting and I'm wondering why? These are patients who actually have had high ESSDAI scores. That's a good question, Andrew. We are all planning as well shortly to initiate studies in Phase III for lupus nephritis. I can't speak to how our peers look at it. And this has been a priority for us, to provide relevant answers to our customers. So focusing in on growth and turning to Slide 10. So we know in this population, there's basically no alternative and lutetium-PSMA has demonstrated superiority versus the standard of care.
Import Duties From Italy To Us, Ina Garten Sun-dried Tomato Dip, Nginx Vs Traefik Performance, White Sox Bobblehead Games, Is Rokka No Yuusha Light Novel Finished, Matisse Footwear Agency Western Boot, Create Soap Envelope Java,
